Loading...
XPAR
ABNX
Market cap155mUSD
Sep 19, Last price  
3.80EUR
1D
-1.81%
1Q
211.48%
Jan 2017
-56.07%
IPO
-70.08%
Name

Abionyx Pharma SA

Chart & Performance

D1W1MN
P/E
—
P/S
28.70
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.79%
Rev. gr., 5y
92.84%
Revenues
5m
-0.86%
00000174,00000675,0005,252,0004,640,0004,600,000
Net income
-4m
L+25.07%
-7,742,000-6,563,000-16,638,000-24,871,000-4,978,000-6,305,0001,849,000-1,886,000-5,830,000-4,303,000-3,518,000-4,400,000
CFO
-4m
L-2.65%
-14,493,000-3,303,000-13,711,000-19,197,000-9,092,000-6,001,000-3,950,000-599,000-6,692,000-3,359,000-3,698,000-3,600,000
Earnings
Sep 24, 2025

Profile

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
URL
https://www.abionyx.com/en/
IPO date
Mar 30, 2015
Employees
62
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,600
-0.86%
4,640
-11.65%
5,252
678.07%
Cost of revenue
5,600
8,030
7,044
Unusual Expense (Income)
NOPBT
(1,000)
(3,390)
(1,792)
NOPBT Margin
Operating Taxes
(1,067)
97
Tax Rate
NOPAT
67
(3,390)
(1,889)
Net income
(4,400)
25.07%
(3,518)
-18.24%
(4,303)
-26.19%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,186
42
BB yield
Debt
Debt current
843
815
870
Long-term debt
1,914
4,358
5,250
Deferred revenue
Other long-term liabilities
407
412
417
Net debt
(611)
1,069
1,950
Cash flow
Cash from operating activities
(3,600)
(3,698)
(3,359)
CAPEX
(104)
(175)
Cash from investing activities
(100)
(130)
(175)
Cash from financing activities
2,800
3,886
(194)
FCF
835
(3,583)
(1,382)
Balance
Cash
3,235
4,104
4,046
Long term investments
133
124
Excess cash
3,138
3,872
3,907
Stockholders' equity
(839)
(1,895)
(2,788)
Invested Capital
11,427
14,259
14,216
ROIC
0.52%
ROCE
EV
Common stock shares outstanding
33,695
29,350
27,967
Price
Market cap
EV
EBITDA
(1,000)
(3,237)
(1,657)
EV/EBITDA
Interest
61
19
61
Interest/NOPBT